Inherited Cancer Registry (ICARE) shared a post on LinkedIn:
“New National Comprehensive Cancer Network® (NCCN®) Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Esophageal, and Gastric Cancer Guidelines (Version 1.2026) were just released on June 16th, 2026!
For the purpose of identifying Lynch syndrome, genetic testing is recommended for all patients with the following (regardless of age):
- Colorectal cancer
- Endometrial (uterine) cancer
- Gastric (stomach) cancer
- Any tumor showing mismatch repair deficiency
There was a ‘category 2b’ distinction for the below scenarios:
- Colorectal cancer diagnosed >50 years
- Gastric cancer diagnosed >50 years
Category 2b means that a treatment is considered appropriate by the panel, but is based on lower-level scientific evidence and does not have uniform consensus among the experts. Specifically, it requires at least 50-84% support from the committee, meaning there is no major disagreement, but also no overwhelming consensus.
Genetic testing (through multi-gene panel testing) was defined to include at a minimum:
- The following genes: APC (including APC promoter 1B), ATM, BMPR1A, BRCA1, BRCA2, CDH1, CTNNA1, Lynch syndrome genes (MLH1, MSH2, EPCAM, MSH6), PALB2, SMAD4, STK11, and TP53.
- The Panel recognizes that all of these genes have not been definitively linked to a raised risk of gastric cancer.
- Testing for KIT may also be considered in families where there is a clinical concern for GI stromal tumors (GIST).
To access these new guidelines, create a free account at NCCN.org and visit the following link.
Through ICARE, we aspire to share cancer-related information that may be of interest. If you have questions or clarifications, please direct them to your healthcare provider.”
Other articles on OncoDaily.